PHASE I/II STUDY OF OSI-774 AND CCI-779 IN RECURRENT MALIGNANT GLIOMA

OSI-774 和 CCI-779 在复发性恶性胶质瘤中的 I/II 期研究

• 批准号: 7375547
• 负责人: MINESH P. MEHTA
• 金额: $ 0.34万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375547
• 关键词: PHASE; II; STUDY; OSI; 774

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) RATIONALE: Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This Phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurrent malignant glioma.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。 （来自 ClinicalTrials.gov 网站） 基本原理：厄洛替尼和替西罗莫司可能通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。 目的：这项 I/II 期试验正在研究替西罗莫司与厄洛替尼一起服用时的副作用和最佳剂量，并观察它们在治疗复发性恶性神经胶质瘤患者方面的效果如何。